SynthesisAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2025

A Meta-analysis of the Regulation of Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin-Kexin Type 9 with Inclisiran.

What the trial testedas reported · 5,208 people · 2025

Range includes no effect

+3%−1% to +9%

Bigger than 1 in 10 for adverse events & safety

As reported

RR 1.03, 95% CI 0.99–1.09

Range includes no effect

−8%−26% to +16%

Bigger than 3 in 10 for adverse events & safety

As reported

RR 0.92, 95% CI 0.74–1.16

the abstract, start to end

… in the placebo group (relative risk [RR] 1.03; 95% CI 0.99-1.09; P = 0.15).

… the inclisiran and placebo groups (RR 0.92; 95% CI 0.74-1.16; P = 0.49).

← favours treatmentfavours comparator →

could be chance

Adverse events & safety

RR 1.030.99–1.09

Adverse events & safety

RR 0.920.74–1.16

PCSK9 inhibitorsAdverse events & safety

PCSK9 inhibitors × adverse events & safetyharms?mixed

unlikelylikely

0.00not counted

← favours treatmentfavours comparator →

more certainless certain

1 / 5